Betrixaban - Wikipedia
In 2011 Merck discontinued joint development. [4] The drug has undergone clinical trials for prevention of embolism after knee surgery [5] and for prevention of stroke following non-valvular atrial fibrillation. [6][7] Betrixaban was also studied in a large phase III clinical trial for extended duration thromboprophylaxis in acute ill patients. [8]
Bevyxxa (betrixaban): Uses, Side Effects, Dosage & Reviews - GoodRx
2021年8月31日 · Bevyxxa (betrixaban) was discontinued and taken off the market in April 2020. It was removed from the market by the manufacturer, Portola, for business reasons. The medication was not discontinued due to safety reasons.
Generic Bevyxxa Availability - Drugs.com
2017年6月23日 · Bevyxxa is a brand name of betrixaban, approved by the FDA in the following formulation (s): BEVYXXA (betrixaban - capsule;oral) Manufacturer: PORTOLA PHARMS INC. Approval date: June 23, 2017. Strength (s): 40MG (discontinued) [RLD], 80MG (discontinued) [RLD] All of the above formulations have been discontinued.
R 3229-1 and PMR 3229-2 and 3229-3. As embodied in the Notice of Permanent Discontinuance of Manufacturing in April 2020, Portola had decided to withdraw Bevyxxa® (betrixaban) capsules, 40 mg and...
Betrixaban (oral route) - Mayo Clinic
2024年2月1日 · Betrixaban is used to prevent venous thromboembolism (VTE) in hospitalized patients at risk for blood clots because of the loss or decreased ability to move around or due to other factors. Betrixaban is a factor Xa inhibitor, an anticoagulant. It works by decreasing the clotting ability of the blood and helps prevent harmful clots from forming ...
Bevyxxa (betrixaban) FDA Approval History - Drugs.com
2017年6月23日 · Bevyxxa FDA Approval History. FDA Approved: Yes (First approved June 23, 2017) Brand name: Bevyxxa. Generic name: betrixaban. Dosage form: Capsules. Company: Portola Pharmaceuticals, Inc. Treatment for: Prevention of Venous Thromboembolism.
Bristol-Meyers Squibb Company, et al.; Withdrawal of Approval of …
2021年3月16日 · SUMMARY: The Food and Drug Administration (FDA or Agency) is withdrawing approval of 19 new drug applications (NDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.
Bevyxxa: Uses, Dosage, Side Effects & Warnings - Drugs.com
2024年9月30日 · Bevyxxa (betrixaban) blocks the activity of certain clotting substances in the blood. Bevyxxa is used to prevent blood clots in adults who have a serious illness and decreased ability to move. Includes uses, side effects, interactions, warnings and more..
FDA approved betrixaban (BEVYXXA, Portola) for the prophylaxis …
On June 23, 2017, the U.S. Food and Drug Administration approved betrixaban (BEVYXXA, Portola) for the prophylaxis of venous thromboembolism (VTE) in adult patients hospitalized for an...
Formulary Drug Review: Betrixaban - PMC - National Center for ...
Betrixaban is approved by the US Food and Drug Administration (FDA) for prophylaxis of venous thromboembolism (VTE) in adult patients hospitalized for an acute medical illness who are at risk for thromboembolic complications due to moderate or severe restricted mobility and other risk factors for VTE. 1,2 The safety and effectiveness of ...
- 某些结果已被删除